In a significant move by the Food and Drug Administration, a quick review was granted for three experimental psychedelic drugs aiming to battle major depression and post-traumatic stress disorder in the United States. This decision, announced on a Friday, reflects a broader shift in the Trump administration's approach toward mental health treatment options involving psychedelics, a class of substances often associated with illicit drug use. This action follows a recent policy change by the Justice Department that eased restrictions on medical marijuana, suggesting a trend towards more liberal attitudes concerning alternative therapies. These developments have been largely motivated by advocacy from war veterans suffering from psychological trauma, pushing for increased research and access to treatments previously dismissed due to their controversial nature. FDA Commissioner Marty Makary emphasized that the human brain's biochemical complexities are not fully understood, particularly in individuals dealing with trauma. He highlighted the urgency of exploring these alternative therapies to aid veterans facing debilitating mental health issues. Critics, however, have raised concerns that the expedited review process might compromise the FDA’s credibility, fearing that it could lead to undue influence from pharmaceutical companies seeking approval for their products without thorough evaluation. Historically, research on psychedelics has been limited due to their illegal status in the U.S., making anecdotal evidence the main source of knowledge. Despite this, experts from the medical community support a more scientific evaluation of these substances, with researchers like Dr. Peg Nopoulos from the University of Iowa advocating for rigorous investigations into the effects of psychedelics like psilocybin and ketamine on conditions such as alcohol use disorder. In light of these new approvals, researchers will now be able to examine the effects of ibogaine and its derivative, noribogaine hydrochloride, for treating addiction, adding to the repertoire of potential solutions for the estimated 28 million Americans experiencing alcohol use disorders. As these developments unfold, the future of psychedelic research seems to be entering a new phase, with increased scrutiny and hope for effective treatment options to enhance mental health care in the United States.